Form 4: Director Receives 15,000 OBIO Restricted Stock Units

Orchestra BioMed Holdings, Inc. Director Jason Aryeh was granted 15,000 restricted stock units vesting in one year.

Summary

• Director Jason Aryeh of Orchestra BioMed Holdings, Inc. (OBIO) was awarded 15,000 restricted stock units (RSUs).
• The grant date for these RSUs was August 7, 2025.
• Each RSU represents a contingent right to receive one share of OBIO Common Stock.
• The RSUs will vest on the one-year anniversary of the grant date, contingent on Mr. Aryeh's continuous service through that date.
• Following this transaction, Mr. Aryeh beneficially owns 107,482 shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally positive as it aligns interests and incentivizes long-term commitment, but it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of RSUs aligns the director's interests with long-term shareholder value.
• Increased beneficial ownership by a director demonstrates confidence in the company's future.

Risks

• Vesting of RSUs is subject to the director's continuous service, meaning the shares are not immediately owned and could be forfeited if service ceases before the vesting date.

Future Outlook

The vesting of the 15,000 restricted stock units is contingent on the director's continuous service through August 7, 2026, indicating a future commitment period.

Industry Context

This filing reflects a common practice in the biotechnology and medical device industry, where equity awards like RSUs are used to compensate directors and align their interests with long-term company performance and shareholder value. Such awards are standard components of executive and director compensation packages aimed at retention and motivation.

Comparison to Industry Standards

• The grant of 15,000 RSUs to a director is a standard form of non-cash compensation in the biotech sector, comparable to practices at companies like Medtronic or Boston Scientific, which frequently use equity awards to incentivize leadership.
• The $0 acquisition price is typical for RSU grants, reflecting their nature as performance or service-based compensation rather than a direct purchase.
• The one-year vesting period is also common for director equity awards, though some companies may opt for multi-year or performance-based vesting schedules depending on their compensation philosophy.

Related Party Transactions

• The RSU grant to a director is a related party transaction, as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of RSUs dilutes existing shareholders slightly upon vesting but aims to align director incentives with shareholder value creation.
• Employees: No direct impact on employees mentioned.

Next Steps

• Vesting of the 15,000 restricted stock units on August 7, 2026, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to a director, which is a standard compensation practice and does not provide new material information to warrant a change in investment recommendation. It indicates continued alignment of director interests with the company's long-term performance but does not reflect significant operational or financial developments.

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Award, Insider Transaction, Jason Aryeh